loader
Please Wait
Applying Filters...

Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    What is Route Evaluation & Development? A CDMO that can optimize your API synthesis process early during technology transfer will reduce the risk of project delay or failure. That will also help your molecule run more efficiently in their plant. And time is money. Most medicinal chemists design novel active pharmaceutical ingredients (APIs) to secure a patent and IP protection, not to create a scalable production process. That makes sense. They are racing against the clock, running through fail

    proveris-scientific-Default-Wallpaper
    proveris-scientific-Default-Wallpaper
    Previous
    Next
    Filters Filter
    ×
    FILTER DATA :

    filter

    Aesica Pharmaceuticals Limited

    Bellen Chemistry

    Bioindustria L.I.M. Spa

    Biolink LifeSciences

    CARBOGEN AMCIS AG

    CLEARSYNTH LABS LIMITED

    Cambrex Corporation

    Cayman Chemical Company Inc

    ChemCon GmbH

    Eurofins CDMO

    Evotec

    Laboratorium Ofichem B.V

    M2i Group

    Minakem

    Nanjing Dorra Pharmaceutical Technology Co.,Ltd

    PMC Isochem

    POLYPHARMA TECH & SCIENCES

    SANOFI Active Ingredient Solutions

    Siegfried AG

    UQUIFA

    ZCL Chemicals Limited

    filter

    CHINA

    FRANCE

    GERMANY

    INDIA

    ITALY

    NETHERLANDS

    SPAIN

    SWITZERLAND

    UNITED KINGDOM

    UNITED STATES

    Close
    4